% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

rojospan 4 posts  |  Last Activity: Jul 9, 2016 7:27 PM Member since: Apr 27, 2016
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Phase IV orkambi to see if this new pill bottle ( smart phone like) will improve patient adherence and compliance to the drug. Also VX 970 has added 5 th arm for VRTX sponsored Small call lung cancer for patients who show resistance to platinum based regimen. VX150 has finished phase 2A trial recruitment for knee osteoarthritis.

  • rojospan by rojospan Jun 6, 2016 8:14 PM Flag

    VX 661 has generic name now. It is expected that IVA/TEZA combo will be available in late 2017.

  • Spero therapeutics has acquired VXc 486 and VXc 100 with upfront payment and development mile stone payments. Spero has top notch ID guys on board. World need this drug. Drug works well in multidrug resistant tuberculosis by inhibiting gyrase B and also topoisomerase IV.
    Enterome bio has open an office in Kindle Square and has acquired D-Mannose inhibitor patent license for EB 8018 as FmH antagonist for E. Coli.
    JNJ should release plans for phase III of JNJ63623872 ( VX 787). JNJ had acquired Alios biopharma and thus Alios protease inhibitor for influenza and moving it as well in clinical trial.

  • to show any statistical benefit or improvement in FEV-1 in the Parion/ Vertex phase II CF trial alone and with saline. This result is similar to trials done with inhaled Amiloride on CF patients in the past i.e ENaC inhibitors don't work. It is a big blow for this drug development in non CF lung indication like PCD and bronchiectasis which were planned in the second half of 2016. We are paying 1.2 B for a failed drug, just like Virochem and Alios failed programs in the recent years.
    VX 150 program in osteoarthritis is going to face cartilage damage issues with FDA just like JNJ/ AMGN osteoarthritis drug due to worsening joint damage after un-inhibited use of knee joint from lack of pain feelings. CRISPR program has no legs, just theory and R&D expanses. This company need to be sold.

94.98+1.09(+1.16%)12:08 PMEDT